{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:27:50Z","timestamp":1787023670704,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10067-026-08270-0","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:58:41Z","timestamp":1783299521000},"page":"4833-4843","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world retention of nintedanib and factors associated with treatment discontinuation in connective tissue disease\u2013associated interstitial lung disease: a retrospective cohort study of 92 patients"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5053-5933","authenticated-orcid":false,"given":"Takashi","family":"Yamane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"8","key":"8270_CR1","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/art.42860","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD et al (2024) 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol 76(8):1201\u20131213. https:\/\/doi.org\/10.1002\/art.42860","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"8270_CR2","doi-asserted-by":"publisher","first-page":"04320","DOI":"10.1016\/j.ard.2025.08.021","volume":"S0003\u20134967","author":"KM Antoniou","year":"2025","unstructured":"Antoniou KM, Distler O, Gheorghiu AM, Moor CC, Vikse J, Bizymi N et al (2025) ERS\/EULAR clinical practice guidelines for connective tissue diseases associated interstitial lung disease. Ann Rheum Dis S0003\u20134967(25):04320\u201304321. https:\/\/doi.org\/10.1016\/j.ard.2025.08.021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8270_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L et al (2020) Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 8(5):453\u2013460. https:\/\/doi.org\/10.1016\/S2213-2600(20)30036-9","journal-title":"Lancet Respir Med"},{"issue":"6","key":"8270_CR4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.42075","volume":"74","author":"EL Matteson","year":"2022","unstructured":"Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S et al (2022) Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial. Arthritis Rheumatol 74(6):1039\u20131047. https:\/\/doi.org\/10.1002\/art.42075","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"8270_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/resp.14452","volume":"28","author":"Y Inoue","year":"2023","unstructured":"Inoue Y, Wells AU, Song JW, Xu Z, Kitamura H, Suda T et al (2023) Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: results from the INBUILD trial. Respirology 28(5):465\u2013474. https:\/\/doi.org\/10.1111\/resp.14452","journal-title":"Respirology"},{"issue":"4","key":"8270_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/resp.13647","volume":"25","author":"JW Song","year":"2020","unstructured":"Song JW, Ogura T, Inoue Y, Xu Z, Quaresma M, Stowasser S et al (2020) Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: results from INPULSIS\u00ae-ON. Respirology 25(4):410\u2013416. https:\/\/doi.org\/10.1111\/resp.13647","journal-title":"Respirology"},{"issue":"1","key":"8270_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/14397595.2020.1751402","volume":"31","author":"M Kuwana","year":"2021","unstructured":"Kuwana M, Ogura T, Makino S, Homma S, Kondoh Y, Saito A et al (2021) Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: a Japanese population analysis of the SENSCIS trial. Mod Rheumatol 31(1):141\u2013150. https:\/\/doi.org\/10.1080\/14397595.2020.1751402","journal-title":"Mod Rheumatol"},{"issue":"2","key":"8270_CR8","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s12325-024-03079-2","volume":"42","author":"Y Inoue","year":"2025","unstructured":"Inoue Y, Ogura T, Azuma A, Kondoh Y, Homma S, Muraishi K et al (2025) Real-world safety, tolerability and effectiveness of nintedanib in patients with idiopathic pulmonary fibrosis: final report of post-marketing surveillance in Japan. Adv Ther 42(2):1075\u20131093. https:\/\/doi.org\/10.1007\/s12325-024-03079-2","journal-title":"Adv Ther"},{"key":"8270_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152891","volume":"76","author":"K Suzuki","year":"2026","unstructured":"Suzuki K, Akiyama M, Shimanuki K, Fukui H, Kaneko Y (2026) Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort. Semin Arthritis Rheum 76:152891. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152891","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"8270_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A et al (2021) Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med 9(1):96\u2013106. https:\/\/doi.org\/10.1016\/S2213-2600(20)30330-1","journal-title":"Lancet Respir Med"},{"issue":"10","key":"8270_CR11","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s00296-024-05695-1","volume":"44","author":"S Panopoulos","year":"2024","unstructured":"Panopoulos S, Tzilas V, Bournia VK, Tektonidou MG, Sfikakis PP (2024) Tocilizumab plus nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational study. Rheumatol Int 44(10):1959\u20131966. https:\/\/doi.org\/10.1007\/s00296-024-05695-1","journal-title":"Rheumatol Int"},{"issue":"18","key":"8270_CR12","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y et al (2019) Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 381(18):1718\u20131727. https:\/\/doi.org\/10.1056\/NEJMoa1908681","journal-title":"N Engl J Med"},{"issue":"9","key":"8270_CR13","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 205(9):e18\u2013e47. https:\/\/doi.org\/10.1164\/rccm.202202-0399ST","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"8270_CR14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.78750","volume":"17","author":"T Nakamura","year":"2025","unstructured":"Nakamura T, Jinta T, Kitamura A, Tanaka M, So C, Ro S et al (2025) Differences in tolerability of antifibrotic agents between connective tissue disease-associated and non-connective tissue disease-associated interstitial lung disease. Cureus 17(2):e78750. https:\/\/doi.org\/10.7759\/cureus.78750","journal-title":"Cureus"},{"issue":"3","key":"8270_CR15","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s10067-025-07323-0","volume":"44","author":"S M\u0131s\u0131rc\u0131","year":"2025","unstructured":"M\u0131s\u0131rc\u0131 S, Ekin A, Ya\u011f\u0131z B, Co\u015fkun BN, Ba\u015f\u0131b\u00fcy\u00fck F, Birlik AM et al (2025) Treatment with nintedanib is as effective and safe in patients with other connective tissue diseases (CTDs)-interstitial lung disease (ILD) as in patients with systemic sclerosis-ILD: a multicenter retrospective study. Clin Rheumatol 44(3):1187\u20131195. https:\/\/doi.org\/10.1007\/s10067-025-07323-0","journal-title":"Clin Rheumatol"},{"issue":"10","key":"8270_CR16","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1007\/s10067-023-06689-3","volume":"42","author":"M Bare\u0161i\u0107","year":"2023","unstructured":"Bare\u0161i\u0107 M, Novak S, Perkovi\u0107 D, Karanovi\u0107 B, Miri\u0107 F, Radi\u0107 M, Ani\u0107 B (2023) Real world experience with nintedanib in connective tissue disease-related interstitial lung disease: a retrospective cohort study. Clin Rheumatol 42(10):2897\u20132903. https:\/\/doi.org\/10.1007\/s10067-023-06689-3","journal-title":"Clin Rheumatol"},{"issue":"4","key":"8270_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/1756-185X.14611","volume":"26","author":"H Kokubu","year":"2023","unstructured":"Kokubu H, Takeuchi S, Tozawa T, Hisada S, Yamada Y, Itoh Y, Kodera M (2023) Assessing prognostic factors correlating with response to nintedanib for connective tissue disease-associated interstitial lung disease: a real-world single-center study. Int J Rheum Dis 26(4):682\u2013688. https:\/\/doi.org\/10.1111\/1756-185X.14611","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"8270_CR18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6774","volume":"12","author":"R Farooqi","year":"2020","unstructured":"Farooqi R, Kamal A, Burke C (2020) Mycophenolate-induced colitis: a case report with focused review of literature. Cureus 12(1):e6774. https:\/\/doi.org\/10.7759\/cureus.6774","journal-title":"Cureus"},{"issue":"9","key":"8270_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","volume":"58","author":"S Wind","year":"2019","unstructured":"Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T et al (2019) Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet 58(9):1131\u20131147. https:\/\/doi.org\/10.1007\/s40262-019-00766-0","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"8270_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-01974-2","volume":"23","author":"V Cottin","year":"2022","unstructured":"Cottin V, Martinez FJ, Jenkins RG, Belperio JA, Kitamura H, Molina-Molina M et al (2022) Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respir Res 23(1):85. https:\/\/doi.org\/10.1186\/s12931-022-01974-2","journal-title":"Respir Res"},{"issue":"1","key":"8270_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-025-04048-3","volume":"25","author":"K Yazaki","year":"2025","unstructured":"Yazaki K, Matsuyama M, Satoh H, Miyazaki K, Arai N, Ishii Y et al (2025) Gender-age-physiology stage and body mass index are useful predictors of nintedanib discontinuation and prognosis in patients with idiopathic pulmonary fibrosis and progressive fibrotic interstitial lung diseases. BMC Pulm Med 25(1):564. https:\/\/doi.org\/10.1186\/s12890-025-04048-3","journal-title":"BMC Pulm Med"},{"key":"8270_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107603","volume":"225","author":"E Costa","year":"2024","unstructured":"Costa E, Pedroso AR, Matos R, Cunha Rodrigues M, Padr\u00e3o E, Sousa-Neves J, Rolo R (2024) Predictive factors for dose reduction and discontinuation of nintedanib in fibrotic interstitial lung diseases: real life data. Respir Med 225:107603. https:\/\/doi.org\/10.1016\/j.rmed.2024.107603","journal-title":"Respir Med"},{"key":"8270_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152710","volume":"72","author":"B Atienza-Mateo","year":"2025","unstructured":"Atienza-Mateo B, Serrano-Combarro A, Loarce Martos J, Vegas-Revenga N, Mart\u00edn L\u00f3pez M, Casta\u00f1eda S et al (2025) Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients. Semin Arthritis Rheum 72:152710. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152710","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"8270_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3899\/jrheum.2024-0976","volume":"52","author":"M Sebastiani","year":"2025","unstructured":"Sebastiani M, Lepri G, Iannone C, Cassione EB, Guggino G, Lo Monaco A et al (2025) Nintedanib in rheumatoid arthritis-related interstitial lung disease: real-world safety profile and risk of side effects and discontinuation. J Rheumatol 52(5):420\u2013425. https:\/\/doi.org\/10.3899\/jrheum.2024-0976","journal-title":"J Rheumatol"},{"issue":"6","key":"8270_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103804","volume":"24","author":"J Narv\u00e1ez","year":"2025","unstructured":"Narv\u00e1ez J, Aguilar-Coll M, Roig-Kim M, Palacios-Olid J, Maym\u00f3-Paituvi P, de Daniel-Bisbe L, LLop D (2025) Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev 24(6):103804. https:\/\/doi.org\/10.1016\/j.autrev.2025.103804","journal-title":"Autoimmun Rev"},{"key":"8270_CR26","doi-asserted-by":"publisher","first-page":"101917","DOI":"10.1016\/j.pupt.2020.101917","volume":"62","author":"Y Hirasawa","year":"2020","unstructured":"Hirasawa Y, Abe M, Terada J, Sakayori M, Suzuki K, Yoshioka K et al (2020) Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 62:101917. https:\/\/doi.org\/10.1016\/j.pupt.2020.101917","journal-title":"Pulm Pharmacol Ther"},{"issue":"6","key":"8270_CR27","doi-asserted-by":"publisher","first-page":"e70046","DOI":"10.1002\/acr2.70046","volume":"7","author":"KD Wysham","year":"2025","unstructured":"Wysham KD, Chang CLA, Singh N, Andrews JS, Wipfler K, Lieber SB et al (2025) Prevalence of frailty and associated factors in a US-wide cohort of rheumatic diseases. ACR Open Rheumatol 7(6):e70046. https:\/\/doi.org\/10.1002\/acr2.70046","journal-title":"ACR Open Rheumatol"},{"issue":"12","key":"8270_CR28","doi-asserted-by":"publisher","first-page":"e851","DOI":"10.1016\/S2665-9913(25)00158-4","volume":"7","author":"GC McDermott","year":"2025","unstructured":"McDermott GC, Gill R, Byrne S, Gagne S, Wang X, Paudel ML et al (2025) Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA. Lancet Rheumatol 7(12):e851\u2013e863. https:\/\/doi.org\/10.1016\/S2665-9913(25)00158-4","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"8270_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/acr.22996","volume":"69","author":"D Sim\u00f5es","year":"2017","unstructured":"Sim\u00f5es D, Ara\u00fajo FA, Severo M, Monjardino T, Cruz I, Carmona L, Lucas R (2017) Patterns and consequences of multimorbidity in the general population: there is no chronic disease management without rheumatic disease management. Arthritis Care Res (Hoboken) 69(1):12\u201320. https:\/\/doi.org\/10.1002\/acr.22996","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"8270_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/MCG.0000000000000752","volume":"51","author":"NA Philip","year":"2017","unstructured":"Philip NA, Ahmed N, Pitchumoni CS (2017) Spectrum of drug-induced chronic diarrhea. J Clin Gastroenterol 51(2):111\u2013117. https:\/\/doi.org\/10.1097\/MCG.0000000000000752","journal-title":"J Clin Gastroenterol"},{"key":"8270_CR31","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5984-25","author":"Y Satonaga","year":"2025","unstructured":"Satonaga Y, Kudoh R, Hata M, Shigenaga T, Komiya K (2025) Ramosetron as a supportive agent to continue nintedanib in patients with interstitial lung disease. Intern Med. https:\/\/doi.org\/10.2169\/internalmedicine.5984-25","journal-title":"Intern Med"},{"issue":"22","key":"8270_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14227914","volume":"14","author":"T Arai","year":"2025","unstructured":"Arai T, Hirose M, Kagawa T, Takeuchi N, Kobayashi T, Inoue Y, Matsuda Y (2025) Effectiveness of a 5-hydroxytryptamine type 3 receptor antagonist for treating nintedanib-induced diarrhea: a prospective observational study. J Clin Med 14(22):7914. https:\/\/doi.org\/10.3390\/jcm14227914","journal-title":"J Clin Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08270-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08270-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08270-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:16:09Z","timestamp":1787022969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08270-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8270"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08270-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Kakogawa Central City Hospital (approval number: #2025\u201344) and was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Given the retrospective nature of the study, the requirement for written informed consent was waived by the ethics committee. Study information was disclosed through an opt-out process. All procedures followed were in accordance with institutional guidelines, and no identifying patient information is included in this manuscript.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TY has received speaker fees from GSK and Eli Lilly Japan K.K. and Boehringer Ingelheim. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}